Literature DB >> 18425494

Iron and inflammation: cross-talk between pathways regulating hepcidin.

Robert E Fleming1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18425494     DOI： 10.1007/s00109-008-0349-8

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN： 0946-2716            Impact factor:   4.599


× No keyword cloud information.
  12 in total

1.  The iron efflux protein ferroportin regulates the intracellular growth of Salmonella enterica.

Authors:  Sabine Chlosta; Douglas S Fishman; Lynne Harrington; Erin E Johnson; Mitchell D Knutson; Marianne Wessling-Resnick; Bobby J Cherayil
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

2.  Distinct requirements for Hfe in basal and induced hepcidin levels in iron overload and inflammation.

Authors:  Marco Constante; Wenlei Jiang; Dongmei Wang; Valérie-Ann Raymond; Marc Bilodeau; Manuela M Santos
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2006-03-24       Impact factor: 4.052

3.  A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression.

Authors:  Rui-Hong Wang; Cuiling Li; Xiaoling Xu; Yin Zheng; Cuiying Xiao; Patricia Zerfas; Sharon Cooperman; Michael Eckhaus; Tracey Rouault; Lopa Mishra; Chu-Xia Deng
Journal:  Cell Metab       Date:  2005-12       Impact factor: 27.287

Review 4.  Hemochromatosis and the enigma of misplaced iron: implications for infectious disease and survival.

Authors:  Sharon Moalem; Eugene D Weinberg; Maire E Percy
Journal:  Biometals       Date:  2004-04       Impact factor: 2.949

5.  Increased hepcidin expression and hypoferraemia associated with an acute phase response are not affected by inactivation of HFE.

Authors:  David M Frazer; Sarah J Wilkins; Kirstin N Millard; Andrew T McKie; Christopher D Vulpe; Gregory J Anderson
Journal:  Br J Haematol       Date:  2004-08       Impact factor: 6.998

6.  The IL-6- and lipopolysaccharide-induced transcription of hepcidin in HFE-, transferrin receptor 2-, and beta 2-microglobulin-deficient hepatocytes.

Authors:  Pauline Lee; Hongfan Peng; Terri Gelbart; Ernest Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-10       Impact factor: 11.205

7.  Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism.

Authors:  Paul B Yu; Charles C Hong; Chetana Sachidanandan; Jodie L Babitt; Donna Y Deng; Stefan A Hoyng; Herbert Y Lin; Kenneth D Bloch; Randall T Peterson
Journal:  Nat Chem Biol       Date:  2007-11-18       Impact factor: 15.040

8.  A bone morphogenetic protein (BMP)-responsive element in the hepcidin promoter controls HFE2-mediated hepatic hepcidin expression and its response to IL-6 in cultured cells.

Authors:  Maria Vittoria Verga Falzacappa; Guillem Casanovas; Matthias W Hentze; Martina U Muckenthaler
Journal:  J Mol Med (Berl)       Date:  2008-04-18       Impact factor: 4.599

9.  The distal location of the iron responsive region of the hepcidin promoter.

Authors:  Jaroslav Truksa; Pauline Lee; Hongfan Peng; Jonathan Flanagan; Ernest Beutler
Journal:  Blood       Date:  2007-07-20       Impact factor: 22.113

10.  Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4.

Authors:  Lan Lin; Erika V Valore; Elizabeta Nemeth; Julia B Goodnough; Victoria Gabayan; Tomas Ganz
Journal:  Blood       Date:  2007-05-31       Impact factor: 22.113
View more
  14 in total

1.  The connectivity map links iron regulatory protein-1-mediated inhibition of hypoxia-inducible factor-2a translation to the anti-inflammatory 15-deoxy-delta12,14-prostaglandin J2.

Authors:  Michael Zimmer; Justin Lamb; Benjamin L Ebert; Mary Lynch; Christopher Neil; Emmett Schmidt; Todd R Golub; Othon Iliopoulos
Journal:  Cancer Res       Date:  2010-03-30       Impact factor: 12.701

Review 2.  Serum hepcidin concentrations and type 2 diabetes.

Authors:  Alex Aregbesola; Sari Voutilainen; Jyrki K Virtanen; Adeola Aregbesola; Tomi-Pekka Tuomainen
Journal:  World J Diabetes       Date:  2015-07-10

3.  Pathways for the regulation of hepcidin expression in anemia of chronic disease and iron deficiency anemia in vivo.

Authors:  Igor Theurl; Andrea Schroll; Manfred Nairz; Markus Seifert; Milan Theurl; Thomas Sonnweber; Hasan Kulaksiz; Guenter Weiss
Journal:  Haematologica       Date:  2011-08-22       Impact factor: 9.941

4.  Hepcidin expression in anemia of chronic disease and concomitant iron-deficiency anemia.

Authors:  Pan-pan Cheng; Xiao-yang Jiao; Xue-hua Wang; Jing-hua Lin; Ying-mu Cai
Journal:  Clin Exp Med       Date:  2010-05-25       Impact factor: 3.984

5.  Time-course analysis of serum hepcidin, iron and cytokines in a C282Y homozygous patient with Schnitzler's syndrome treated with IL-1 receptor antagonist.

Authors:  Marcel van Deuren; Joyce J C Kroot; Dorine W Swinkels
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

Review 6.  Hepcidin modulation in human diseases: from research to clinic.

Authors:  Alberto Piperno; Raffaella Mariani; Paola Trombini; Domenico Girelli
Journal:  World J Gastroenterol       Date:  2009-02-07       Impact factor: 5.742

Review 7.  Regulation of cellular iron metabolism.

Authors:  Jian Wang; Kostas Pantopoulos
Journal:  Biochem J       Date:  2011-03-15       Impact factor: 3.857

Review 8.  Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose.

Authors:  Jorge Eduardo Toblli; Margarita Angerosa
Journal:  Drug Des Devel Ther       Date:  2014-12-11       Impact factor: 4.162

9.  An insight into the relationships between hepcidin, anemia, infections and inflammatory cytokines in pediatric refugees: a cross-sectional study.

Authors:  Sarah Cherian; David A Forbes; Angus G Cook; Frank M Sanfilippo; Erwin H Kemna; Dorine W Swinkels; David P Burgner
Journal:  PLoS One       Date:  2008-12-24       Impact factor: 3.240

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.